JP2021521796A5 - - Google Patents
Info
- Publication number
- JP2021521796A5 JP2021521796A5 JP2020557924A JP2020557924A JP2021521796A5 JP 2021521796 A5 JP2021521796 A5 JP 2021521796A5 JP 2020557924 A JP2020557924 A JP 2020557924A JP 2020557924 A JP2020557924 A JP 2020557924A JP 2021521796 A5 JP2021521796 A5 JP 2021521796A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide according
- nucleotides
- oligonucleotide
- antisense
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023159941A JP2023174697A (ja) | 2018-04-18 | 2023-09-25 | 高コレステロール血症及び関連状態を治療するための、ｐｃｓｋ９を標的とするオリゴヌクレオチド |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862659693P | 2018-04-18 | 2018-04-18 | |
| US62/659,693 | 2018-04-18 | ||
| US201962820558P | 2019-03-19 | 2019-03-19 | |
| US62/820,558 | 2019-03-19 | ||
| PCT/US2019/025253 WO2019204021A1 (en) | 2018-04-18 | 2019-04-01 | Pcsk9 targeting oligonucleotides for treating hypercholesterolemia and related conditions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023159941A Division JP2023174697A (ja) | 2018-04-18 | 2023-09-25 | 高コレステロール血症及び関連状態を治療するための、ｐｃｓｋ９を標的とするオリゴヌクレオチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021521796A JP2021521796A (ja) | 2021-08-30 |
| JP2021521796A5 true JP2021521796A5 (enExample) | 2022-04-07 |
| JP7357002B2 JP7357002B2 (ja) | 2023-10-05 |
Family
ID=68239855
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020557924A Active JP7357002B2 (ja) | 2018-04-18 | 2019-04-01 | 高コレステロール血症及び関連状態を治療するための、ｐｃｓｋ９を標的とするオリゴヌクレオチド |
| JP2023159941A Withdrawn JP2023174697A (ja) | 2018-04-18 | 2023-09-25 | 高コレステロール血症及び関連状態を治療するための、ｐｃｓｋ９を標的とするオリゴヌクレオチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023159941A Withdrawn JP2023174697A (ja) | 2018-04-18 | 2023-09-25 | 高コレステロール血症及び関連状態を治療するための、ｐｃｓｋ９を標的とするオリゴヌクレオチド |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11566248B2 (enExample) |
| EP (1) | EP3765611A4 (enExample) |
| JP (2) | JP7357002B2 (enExample) |
| KR (1) | KR102749200B1 (enExample) |
| CN (1) | CN112368381A (enExample) |
| AU (1) | AU2019255460A1 (enExample) |
| CA (1) | CA3097585A1 (enExample) |
| IL (1) | IL278086A (enExample) |
| MX (1) | MX2020011006A (enExample) |
| WO (1) | WO2019204021A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11597744B2 (en) | 2017-06-30 | 2023-03-07 | Sirius Therapeutics, Inc. | Chiral phosphoramidite auxiliaries and methods of their use |
| JP7357002B2 (ja) * | 2018-04-18 | 2023-10-05 | ディセルナ ファーマシューティカルズ インコーポレイテッド | 高コレステロール血症及び関連状態を治療するための、ｐｃｓｋ９を標的とするオリゴヌクレオチド |
| AU2020268798A1 (en) * | 2019-05-03 | 2021-11-04 | Dicerna Pharmaceuticals, Inc. | Double-stranded nucleic acid inhibitor molecules with shortened sense strands |
| CN115176011B (zh) * | 2019-08-27 | 2025-11-11 | 赛诺菲 | 用于抑制pcsk9的组合物和方法 |
| WO2022089486A1 (zh) * | 2020-10-28 | 2022-05-05 | 江苏柯菲平医药股份有限公司 | 抑制PCSK9基因表达的siRNA及其修饰物与应用 |
| CN114634929A (zh) * | 2020-12-16 | 2022-06-17 | 施能康生物科技有限公司 | 靶向前蛋白转化酶枯草杆菌转化酶的核酸及其用途 |
| WO2023017004A1 (en) * | 2021-08-09 | 2023-02-16 | Cargene Therapeutics Pte. Ltd. | Inhibitory nucleic acids for pcsk9 |
| CN115992138A (zh) * | 2021-09-30 | 2023-04-21 | 北京安龙生物医药有限公司 | 用于治疗与pcsk9相关疾病的靶向寡核苷酸 |
| US20250346902A1 (en) * | 2022-01-13 | 2025-11-13 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Rnai agent inhibiting pcsk9 gene expression and application thereof |
| CN119487191A (zh) * | 2022-06-14 | 2025-02-18 | 大睿生物医药科技(上海)有限公司 | 调控PCSK9基因活性的siRNA分子 |
| CN118086311B (zh) * | 2023-05-25 | 2024-08-09 | 苏州时安生物技术有限公司 | 抑制PCSK9基因表达的siRNA、其缀合物和药物组合物及用途 |
| WO2024263915A2 (en) * | 2023-06-21 | 2024-12-26 | Sanegene Bio Usa Inc. | Double stranded rna targeting proprotein convertase subtilisin kexin 9 (pcsk9) and methods of use thereof |
| CN121006363A (zh) * | 2023-09-18 | 2025-11-25 | 广州必贝特医药股份有限公司 | 用于同时抑制两个靶基因表达的siRNA、药物及其应用 |
| CN117106781B (zh) * | 2023-10-16 | 2024-03-22 | 深圳市茵冠生物科技有限公司 | 修饰的核酸及其产品和应用 |
| WO2025096355A1 (en) * | 2023-10-29 | 2025-05-08 | Corsera Llc | Improved sirna for silencing expression of pcsk9 and uses thereof |
| CN118147134B (zh) * | 2023-11-06 | 2025-02-25 | 北京悦康科创医药科技股份有限公司 | 靶向调控PCSK9基因表达的siRNA及其应用 |
| CN117384907B (zh) * | 2023-12-11 | 2024-03-29 | 上海鼎新基因科技有限公司 | 抑制PCSK9表达的siRNA分子及其应用 |
| CN118109463B (zh) * | 2024-01-31 | 2025-02-21 | 北京悦康科创医药科技股份有限公司 | 靶向PCSK9基因的siRNA及其应用 |
| WO2026026812A1 (zh) * | 2024-07-29 | 2026-02-05 | 成都先衍生物技术有限公司 | 一种具有双靶点基因抑制作用的核酸缀合物及其应用 |
| WO2026026811A1 (zh) * | 2024-07-29 | 2026-02-05 | 成都先衍生物技术有限公司 | 一种具有双靶点基因抑制作用的核酸缀合物及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101484588B (zh) * | 2006-05-11 | 2013-11-06 | 阿尔尼拉姆医药品有限公司 | 抑制pcsk9基因表达的组合物和方法 |
| CA2658183A1 (en) * | 2006-07-17 | 2008-01-24 | Sirna Therapeutics Inc. | Rna interference mediated inhibition of proprotein convertase subtilisin kexin 9 (pcsk9) gene expression using short interfering nucleic acid (sina) |
| CA2670563A1 (en) * | 2006-11-27 | 2008-06-05 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
| WO2008109369A2 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting tnf gene expression and uses thereof |
| WO2009114475A2 (en) * | 2008-03-09 | 2009-09-17 | Intradigm Corporation | Compositions comprising human pcsk9 and apolipoprotein b sirna and methods of use |
| WO2010078536A1 (en) * | 2009-01-05 | 2010-07-08 | Rxi Pharmaceuticals Corporation | Inhibition of pcsk9 through rnai |
| JP5894913B2 (ja) | 2009-06-15 | 2016-03-30 | アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｐｃｓｋ９遺伝子を標的とする、脂質で製剤化されたｄｓｒｎａ |
| WO2012058693A2 (en) | 2010-10-29 | 2012-05-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of pcsk9 genes |
| DK3569711T3 (da) * | 2014-12-15 | 2021-02-22 | Dicerna Pharmaceuticals Inc | Ligandmodificerede dobbeltstrengede nukleinsyrer |
| JP7357002B2 (ja) | 2018-04-18 | 2023-10-05 | ディセルナ ファーマシューティカルズ インコーポレイテッド | 高コレステロール血症及び関連状態を治療するための、ｐｃｓｋ９を標的とするオリゴヌクレオチド |
-
2019
- 2019-04-01 JP JP2020557924A patent/JP7357002B2/ja active Active
- 2019-04-01 CN CN201980041119.4A patent/CN112368381A/zh not_active Withdrawn
- 2019-04-01 EP EP19787636.0A patent/EP3765611A4/en not_active Withdrawn
- 2019-04-01 WO PCT/US2019/025253 patent/WO2019204021A1/en not_active Ceased
- 2019-04-01 US US17/048,846 patent/US11566248B2/en active Active
- 2019-04-01 MX MX2020011006A patent/MX2020011006A/es unknown
- 2019-04-01 AU AU2019255460A patent/AU2019255460A1/en not_active Withdrawn
- 2019-04-01 CA CA3097585A patent/CA3097585A1/en active Pending
- 2019-04-01 KR KR1020207032782A patent/KR102749200B1/ko active Active
-
2020
- 2020-10-15 IL IL278086A patent/IL278086A/en unknown
-
2022
- 2022-11-30 US US18/060,406 patent/US20230250435A1/en not_active Abandoned
-
2023
- 2023-09-25 JP JP2023159941A patent/JP2023174697A/ja not_active Withdrawn